CRDL

Cardiol Therapeutics Inc

NASDAQ

Add Alert

CRDL

Cardiol Therapeutics Inc

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Monksdream PremiumMember

04/22/24 12:01 PM

Post #125

Re: #124: @Sirpeter - Small caps are getting hammered

Russell 2000 ETF 12 months

Sirpeter

04/22/24 11:58 AM

Post #124

Re: #123: @Monksdream - CRDL under $2

Small caps are getting hammered

Monksdream PremiumMember

04/20/24 12:46 PM

Post #123

Re: #120: @Sirpeter - Taking names and kicking ass...

CRDL under $2

Monksdream PremiumMember

03/24/24 3:06 PM

Post #122

Re: #120: @Sirpeter - Taking names and kicking ass...

CRDL 10Q due 3/26
Next day settlement 5/28 per SEC mandate

TrendTrade2016 PremiumMember

02/29/24 1:43 PM

Post #121

CRDL...MONSTER BREAK OUT!

Sirpeter

02/29/24 1:31 PM

Post #120

Taking names and kicking ass...

TrendTrade2016 PremiumMember

02/29/24 12:27 PM

Post #119

CRDL..HERES 2 BUCKS...MASTER CALLS THE BIGGEST PLAYS ON THE INTERNET.!!

Sirpeter

02/29/24 12:07 PM

Post #118

Next push.. ready to go

TrendTrade2016 PremiumMember

02/28/24 1:19 PM

Post #117

Re: #116: @TrendTrade2016 - CRDL monster move here, another magical trend call!

CRDL...READY TO BREAK 2 BUCKS...WHAT A CALL....

TrendTrade2016 PremiumMember

02/28/24 12:57 PM

Post #116

CRDL monster move here, another magical trend call!

Monksdream PremiumMember

02/28/24 12:36 PM

Post #115

Re: #114: @Sirpeter - Monster play ahead...

I think Investors Hub has resolved the hack

Sirpeter

02/28/24 10:18 AM

Post #114

Re: #113: @Monksdream - CRDL new 52 week high

Monster play ahead...

Monksdream PremiumMember

02/27/24 4:33 PM

Post #113

CRDL new 52 week high

Sirpeter

02/26/24 10:28 AM

Post #112

Re: #111: @TrendTrade2016 - CRDL////BREAK OUT

Good call boss...moving up

TrendTrade2016 PremiumMember

02/26/24 10:15 AM

Post #111

CRDL////BREAK OUT

glenn1919

02/24/24 10:17 AM

Post #110

CRDL...............................................https://stockcharts.com/h-sc/ui?s=CRDL&p=W&b=5&g=0&id=p86431144783

Sirpeter

02/22/24 10:56 AM

Post #109

Re: #108: @TrendTrade2016 - CRDL....BLASTING UP

Added

TrendTrade2016 PremiumMember

02/20/24 2:25 PM

Post #108

CRDL....BLASTING UP

TrendTrade2016 PremiumMember

02/20/24 10:35 AM

Post #107

CRDL...CLEAN 1.62 BREAK OUT!!!

TrendTrade2016 PremiumMember

02/20/24 10:13 AM

Post #106

CRDL...BREAK OUT ON THE WEEKLY....VERY NICE

subslover

02/15/24 8:12 AM

Post #105

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Newsfile Corp.
Newsfile Corp
Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II Study

This is a Designated News Release.

Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") for the Company's lead small molecule drug candidate for the treatment of pericarditis, which includes recurrent pericarditis. CardiolRx™ is currently in Phase II clinical trials for recurrent pericarditis and acute myocarditis.

"The FDA's decision was based on pre-clinical data combined with initial clinical data from the Company's MAvERIC-Pilot Phase II study," commented Dr. Andrew Hamer, Cardiol Therapeutics' Chief Medical Officer and Head of Research & Development. "This designation reinforces the potential of CardiolRx™ to improve the lives of patients suffering with recurrent pericarditis, a debilitating heart disease associated with symptoms that adversely affect quality of life and physical activity."

The FDA grants ODD to a drug or biological product to prevent, diagnose, or treat a rare disease or conditions that affect fewer than 200,000 people in the United States. ODD provides benefits to sponsors including potential seven-year marketing exclusivity, exemptions from certain FDA fees, and tax credits for qualified clinical trials. Products with ODD may also qualify for accelerated regulatory review via Fast Track, Breakthrough Therapy, or Priority Review designations.

MAvERIC-Pilot (NCT05494788) is a Phase II open-label pilot study investigating the tolerance, safety, and effect of CardiolRx™ administered to patients with recurrent pericarditis. In addition to standard safety assessments, MAvERIC-Pilot is designed to evaluate improvement in objective measures of this rare disease. The primary efficacy endpoint is the change, from baseline to eight weeks, in patient-reported pericarditis pain using an 11-point numeric rating scale ("NRS"). The NRS is a validated clinical tool employed across multiple conditions with acute and chronic pain, including previous studies of recurrent pericarditis. Secondary endpoints include the NRS score after 26 weeks of treatment, and changes in circulating levels of C-reactive protein, a commonly used clinical marker of inflammation. Importantly, the study will assess freedom from pericarditis recurrence.

Recurrent pericarditis refers to inflammation of the pericardium (the membrane or sac that surrounds the heart) that follows an initial episode (frequently resulting from a viral infection). Patients may have multiple recurrences. Symptoms include debilitating chest pain, shortness of breath, and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations. Significant accumulation of pericardial fluid and scarring can progress to life-threatening constriction of the heart. The only FDA-approved therapy for recurrent pericarditis, launched in 2021, is costly and is primarily used as a third-line intervention. On an annual basis, the number of patients in the United States having experienced at least one recurrence is estimated at 38,000. Approximately 60% of patients with multiple recurrences (>1) still suffer for longer than 2 years, and one third are still impacted at 5 years. Hospitalization due to recurrent pericarditis is often associated with a 6-8-day length of stay and cost per stay is estimated to range between $20,000 and $30,000 in the United States.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

Cardiol has received Investigational New Drug Application authorization from the FDA to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: (i) a Phase II multi-center open-label pilot study in recurrent pericarditis (the MAvERIC-Pilot study; NCT05494788), an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fati

Billy75

12/06/23 5:33 PM

Post #104

Wife just saw this company today in Sarasota area for luncheon. What is the deal with them? They are going NASDAQ so I’m assuming they have to get this to $5 a share, right?

12yearplan PremiumMember

03/29/23 10:16 AM

Post #102

Market seems to have liked the update today:
https://stockhouse.com/news/press-releases/2023/03/29/cardiol-therapeutics-announces-year-end-2022-update-on-operations

12yearplan PremiumMember

01/20/23 11:04 AM

Post #101

12yearplan PremiumMember

11/11/22 9:33 AM

Post #100

Filings says it all - lean and mean:
https://www.sec.gov/Archives/edgar/data/1702123/000110465922117212/tm2227599d1_ex99-1.htm
https://quantisnow.com/insight/3668667
$CRDL

12yearplan PremiumMember

11/10/22 8:51 AM

Post #99

Re: #98: @Porterhouse10 - Share price says it all $CRDL

Yes, screamin' buy at historical lows..

Porterhouse10 Free

11/09/22 6:31 PM

Post #98

Re: #97: @12yearplan - Don't know Porter. Looks like the market is

Share price says it all $CRDL

12yearplan PremiumMember

11/07/22 10:57 AM

Post #97

Re: #96: @Porterhouse10 - Where's Steve Grasso now? Lmao

Don't know Porter. Looks like the market is likin' the news today and why not I suppose - drugs seem to be workin':

https://stockhouse.com/news/press-releases/2022/11/07/cardiol-therapeutics-announces-study-results-demonstrating-protective-effects-of#BBSL20221107

Porterhouse10 Free

08/27/22 6:53 AM

Post #96

Where's Steve Grasso now? Lmao

Porterhouse10 Free

03/09/22 3:58 PM

Post #95

Grasso's I'm an Advisor to $CRDL pumps are working, people shorting his picks now

12yearplan PremiumMember

02/06/22 10:01 PM

Post #94

Re: #93: @Porterhouse10 - Trading sideways a bit here, not a bad sign

Don't lose at this price point historically; always time I suppose ;)
CRDL$
.. takin' away the freedom..

Porterhouse10 Free

02/05/22 5:44 PM

Post #93

Re: #92: @12yearplan - Two low ebbs/double bottom - must be a

Trading sideways a bit here, not a bad sign

12yearplan PremiumMember

01/26/22 9:06 PM

Post #92

Re: #91: @Porterhouse10 - Steve Grasso must be so proud!

Two low ebbs/double bottom - must be a time of interest.

Porterhouse10 Free

01/26/22 6:13 PM

Post #91

Steve Grasso must be so proud!

12yearplan PremiumMember

12/22/21 9:23 AM

Post #90

Haven't been following lately but chart looks at low ebb and..

Cardiol Omicron
As Omicron spreads like wildfire and hospitalizations increase, it is highly likely Cardiol Rx will be fast tracked. Retail investors have short memories but this is going to be huge: "High-risk patients with Cardiovascular Disease (CVD), hospitalized with COVID-19 CardiolRx Cardiol has received approval from the U.S. Food and Drug Administration for its Investigational New Drug application to conduct a Phase II/III clinical trial investigating the efficacy and safety of CardiolRx in the treatment of hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease".

Porterhouse10 Free

11/04/21 11:13 AM

Post #89

Looks like another Steve Grasso disappointment, chalk up another

srloan

09/07/21 10:40 AM

Post #88

Boom time coming soon !!!

Porterhouse10 Free

08/24/21 7:45 PM

Post #87

Steve Grasso

Renee

08/10/21 6:43 PM

Post #86

CRTPF changed to CRDL. Moved to the Nasdaq from the OTC:

https://www.sec.gov/Archives/edgar/data/1702123/000106299321007173/form6k.htm

https://otce.finra.org/otce/dailyList?viewType=Deletions

Tiresias

12/01/20 10:24 AM

Post #85

Re: #84: @DoctorRutch - This is very close to turning right around.

Can I undo my seat belt? It has been almost three weeks and the ride has not moved.

DoctorRutch Free

11/12/20 5:52 AM

Post #84

This is very close to turning right around. Buckle up

Tiresias

10/28/20 1:08 PM

Post #83

Re: #82: @DoctorRutch - Watch for an influx of buying from houses

Really? Watching, so far nothing, no "short squeeze" as you inferred, share price falling. Do you see an influx? If so, can you point it out. When I see pumping on the message board usually the sign to stay away from it for the time being. People trying to get out from the last bump.

DoctorRutch Free

10/21/20 7:03 AM

Post #82

Watch for an influx of buying from houses that were short Cardiol. It’s to difficult to short this play with a phase II & III going on with expected fantastic results. Easy double from here boys.

barnyarddog Free

10/20/20 4:00 PM

Post #81

https://twitter.com/CardiolRx/status/1318516310637187072/photo/1

barnyarddog Free

10/20/20 3:44 PM

Post #80

FDA Approves Landmark COVID/Heart/CBD Clinical Trial

September 30, 2020
https://biotechstocktrader.com/fda-approves-landmark-covid-heart-cbd-clinical-trial/

barnyarddog Free

10/20/20 3:33 PM

Post #79

September 25, 2020 Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II/III COVID-19 Trial

Trial will take place at major U.S. centers and examine the cardioprotective properties of CardiolRx™ in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease (CVD)

https://www.cardiolrx.com/cardiol-therapeutics-receives-fda-approval-for-investigational-new-drug-ind-application-for-phase-ii-iii-covid-19-trial/

barnyarddog Free

10/20/20 3:30 PM

Post #78

Re: #77: @barnyarddog - CardiolRx is a cannabidiol formulation being developed for

https://www.cardiolrx.com/investors/press-releases/

barnyarddog Free

10/20/20 3:25 PM

Post #77

Re: #76: @barnyarddog - Cardiol Therapeutics’ Cortalex™ CBD Now Available Exclusively Online

CardiolRx is a cannabidiol formulation being developed for the treatment of inflammatory cardiovascular conditions.

https://www.cardiolrx.com/products/cardiolrx-cbd/

barnyarddog Free

10/20/20 3:14 PM

Post #76

Cardiol Therapeutics’ Cortalex™ CBD Now Available Exclusively Online at Medical Cannabis by Shoppers Inc.

October 20, 2020

https://biotechstocktrader.com/cardiol-therapeutics-cortalex-cbd-now-available-exclusively-online-at-medical-cannabis-by-shoppers-inc/

....The Company recently received approval from the U.S. FDA for its Investigational New Drug (IND) application to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead product, CardiolRx™, in hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease. CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP, and THC-free (<10 ppm).

DoctorRutch Free

10/16/20 12:25 PM

Post #75

This is heading straight to $7.00 to $8.00 !!!!!!!! Have you guys seen who is involved in the phase 2 and three trials? Do your homework here. This one is a complete no brainer for me and my group. During the second wave, this could bring down the mortality rate. This has global implications and could catapult this company into the global medical spotlight. Buckle up peeps, buckle up!